Exatecan Intermediate 1

• Description:

  Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631) . Exatecan is a DNA topoisomerase I inhibitor with anticancer effects[1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  ADC Payload; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/exatecan-intermediate-1.html

• Purity:

  99.99

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C1[C@] (O) (CC) C (C=C23) =C (CO1) C (N3CCC2=O) =O

• Molecular Formula:

  C13H13NO5

• Molecular Weight:

  263.25

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Weng W, et al. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13 (4) :950-973. |[2]Zhang Hongwei, et al. Intermediate for synthesizing camptothecin derivatives using exatecan mesylate and its preparation method and application. China, CN111470998. 2020-07-31. |[3]Conilh L, et al. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel) . 2021 Mar 9;14 (3) :247.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Camptothecins

• CAS Number:

  110351-94-5